279 related articles for article (PubMed ID: 30717691)
1. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.
Bhargava R; Kalra PA; Hann M; Brenchley P; Hurst H; Hutchison AJ
BMC Nephrol; 2019 Feb; 20(1):37. PubMed ID: 30717691
[TBL] [Abstract][Full Text] [Related]
2. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
Wald R; Rabbat CG; Girard L; Garg AX; Tennankore K; Tyrwhitt J; Smyth A; Rathe-Skafel A; Gao P; Mazzetti A; Bosch J; Yan AT; Parfrey P; Manns BJ; Walsh M
Clin J Am Soc Nephrol; 2017 Jun; 12(6):965-973. PubMed ID: 28550080
[TBL] [Abstract][Full Text] [Related]
3. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
[TBL] [Abstract][Full Text] [Related]
4. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
5. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
6. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
7. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
9. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
[TBL] [Abstract][Full Text] [Related]
11. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.
Ohno M; Ohashi H; Oda H; Yokoyama H; Okada M; Nagaya M; Izumi K; Ito H; Katoh S
Perit Dial Int; 2013; 33(3):297-303. PubMed ID: 23209037
[TBL] [Abstract][Full Text] [Related]
12. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
13. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
[TBL] [Abstract][Full Text] [Related]
14. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Mohammed I; Hutchison AJ
J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
[TBL] [Abstract][Full Text] [Related]
15. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.
Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N
PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324
[TBL] [Abstract][Full Text] [Related]
16. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
[TBL] [Abstract][Full Text] [Related]
17. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]